FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282970469> ?p ?o ?g. }

• W4282970469 endingPage "CT256" @default.
• W4282970469 startingPage "CT256" @default.
• W4282970469 abstract "Abstract Intravenous irinotecan hydrochloride (IRN-IV) is approved for the treatment of adult colorectal cancer. IRN-IV is also widely used off-label for a range of adult and pediatric solid tumors including recurrent Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, hepatoblastoma, Wilms tumor, gynecologic cancers, lung cancer and medulloblastoma. Recently, commercially available intravenous irinotecan has been administered orally (IRN-IVPO) in pediatric patients to improve convenience, reduce in-clinic time and overall cost of treatment. Unfortunately, the palatability of the intravenous preparation is poor, leading to reduced compliance especially in younger pediatric patients. Development of an advanced formulation to improve tolerability and patient compliance is an important unmet need. VAL-413 is a novel formulation developed to improve palatability of oral irinotecan. We will report on an ongoing Phase 1-2 first-in-human clinical trial of VAL-413, designed to test the hypothesis that VAL-413 improves palatability without significant pharmacokinetic differences from IRN-IVPO using intra-patient comparison of pharmacokinetic profiles. The evaluation of two dose levels will help to formally define a recommended dose for advanced clinical studies. Trial Design: Patients ≥ 1 year of age or ≤ 30 years of age with recurrent pediatric solid tumors and adequate bone marrow, renal and liver function, for whom irinotecan therapy is a treatment option, are eligible. Up to 20 eligible patients will receive VAL-413 90mg/m2/day or 110mg/m2/day using a standard 3 + 3 design. During the first cycle of treatment, each patient will receive four daily doses of VAL-413 and one daily dose of IRN-IVPO, together with five (5) days of concurrent temozolomide. Pharmacokinetic assessments will follow both VAL-413 and IRN-IVPO administration using a limited sampling strategy. During all subsequent cycles, only VAL-413 will be given with temozolomide in 5-day courses administered every 21 days. Up to 17 cycles of treatment may be administered on this study. Outcome Measures: Toxicity is assessed by NCI CCTCAEv5; tumor response is assessed by RECIST 1.1. A palatability survey instrument will assess palatability of VAL-413 vs. IRN-IVPO; and comparative intrapatient pharmacokinetics of irinotecan and its metabolites will be assessed in all patients. Citation Format: James Geller, Patrick Thompson, Javier Oesterheld, Dennis M. Brown, Jeffrey Bacha, Sarath Kanekal, Lorena Lopez, Markos Leggas, Neil Sankar, Noymi Yam, Lars M. Wagner. A pilot clinical study of VAL-413 (Orotecan®, oral irinotecan HCl) in patients with recurrent pediatric solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT256." @default.
• W4282970469 created "2022-06-17" @default.
• W4282970469 creator A5008062466 @default.
• W4282970469 creator A5014794937 @default.
• W4282970469 creator A5024860663 @default.
• W4282970469 creator A5046497194 @default.
• W4282970469 creator A5050440486 @default.
• W4282970469 creator A5058009042 @default.
• W4282970469 creator A5058782198 @default.
• W4282970469 creator A5064134740 @default.
• W4282970469 creator A5066731966 @default.
• W4282970469 creator A5074724246 @default.
• W4282970469 creator A5091035596 @default.
• W4282970469 date "2022-06-15" @default.
• W4282970469 modified "2023-09-24" @default.
• W4282970469 title "Abstract CT256: A pilot clinical study of VAL-413 (Orotecan®, oral irinotecan HCl) in patients with recurrent pediatric solid tumors" @default.
• W4282970469 doi "https://doi.org/10.1158/1538-7445.am2022-ct256" @default.
• W4282970469 hasPublicationYear "2022" @default.
• W4282970469 type Work @default.
• W4282970469 citedByCount "0" @default.
• W4282970469 crossrefType "journal-article" @default.
• W4282970469 hasAuthorship W4282970469A5008062466 @default.
• W4282970469 hasAuthorship W4282970469A5014794937 @default.
• W4282970469 hasAuthorship W4282970469A5024860663 @default.
• W4282970469 hasAuthorship W4282970469A5046497194 @default.
• W4282970469 hasAuthorship W4282970469A5050440486 @default.
• W4282970469 hasAuthorship W4282970469A5058009042 @default.
• W4282970469 hasAuthorship W4282970469A5058782198 @default.
• W4282970469 hasAuthorship W4282970469A5064134740 @default.
• W4282970469 hasAuthorship W4282970469A5066731966 @default.
• W4282970469 hasAuthorship W4282970469A5074724246 @default.
• W4282970469 hasAuthorship W4282970469A5091035596 @default.
• W4282970469 hasConcept C112705442 @default.
• W4282970469 hasConcept C121608353 @default.
• W4282970469 hasConcept C126322002 @default.
• W4282970469 hasConcept C141071460 @default.
• W4282970469 hasConcept C142724271 @default.
• W4282970469 hasConcept C143998085 @default.
• W4282970469 hasConcept C197934379 @default.
• W4282970469 hasConcept C2776581026 @default.
• W4282970469 hasConcept C2776694085 @default.
• W4282970469 hasConcept C2778256501 @default.
• W4282970469 hasConcept C2778375690 @default.
• W4282970469 hasConcept C2780259306 @default.
• W4282970469 hasConcept C2780844630 @default.
• W4282970469 hasConcept C2993561819 @default.
• W4282970469 hasConcept C526805850 @default.
• W4282970469 hasConcept C535046627 @default.
• W4282970469 hasConcept C71924100 @default.
• W4282970469 hasConceptScore W4282970469C112705442 @default.
• W4282970469 hasConceptScore W4282970469C121608353 @default.
• W4282970469 hasConceptScore W4282970469C126322002 @default.
• W4282970469 hasConceptScore W4282970469C141071460 @default.
• W4282970469 hasConceptScore W4282970469C142724271 @default.
• W4282970469 hasConceptScore W4282970469C143998085 @default.
• W4282970469 hasConceptScore W4282970469C197934379 @default.
• W4282970469 hasConceptScore W4282970469C2776581026 @default.
• W4282970469 hasConceptScore W4282970469C2776694085 @default.
• W4282970469 hasConceptScore W4282970469C2778256501 @default.
• W4282970469 hasConceptScore W4282970469C2778375690 @default.
• W4282970469 hasConceptScore W4282970469C2780259306 @default.
• W4282970469 hasConceptScore W4282970469C2780844630 @default.
• W4282970469 hasConceptScore W4282970469C2993561819 @default.
• W4282970469 hasConceptScore W4282970469C526805850 @default.
• W4282970469 hasConceptScore W4282970469C535046627 @default.
• W4282970469 hasConceptScore W4282970469C71924100 @default.
• W4282970469 hasIssue "12_Supplement" @default.
• W4282970469 hasLocation W42829704691 @default.
• W4282970469 hasOpenAccess W4282970469 @default.
• W4282970469 hasPrimaryLocation W42829704691 @default.
• W4282970469 hasRelatedWork W2007539997 @default.
• W4282970469 hasRelatedWork W2030363482 @default.
• W4282970469 hasRelatedWork W2124064787 @default.
• W4282970469 hasRelatedWork W2356215202 @default.
• W4282970469 hasRelatedWork W2904856500 @default.
• W4282970469 hasRelatedWork W2969533880 @default.
• W4282970469 hasRelatedWork W2977802423 @default.
• W4282970469 hasRelatedWork W3082107997 @default.
• W4282970469 hasRelatedWork W3083761066 @default.
• W4282970469 hasRelatedWork W4282970469 @default.
• W4282970469 hasVolume "82" @default.
• W4282970469 isParatext "false" @default.
• W4282970469 isRetracted "false" @default.
• W4282970469 workType "article" @default.